DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20852

Our STN: BL 125085/74

JUN 2 0 2006

Genentech, Incorporated
Attention: Robert L. Garnick, Ph.D.
Senior Vice President, Regulatory Affairs, Quality and Compliance
1 DNA Way, MS #242
South San Francisco, CA 94080

Dear Dr. Garnick:

Your request to supplement your biologics license application for Bevacizumab to expand the indication to include use as an adjunct to chemotherapy for the second-line treatment of patients with metastatic colorectal cancer, has been approved.

This fulfills your commitment to provide the final study report for study E3200, examining the comparative safety and effectiveness of single agent Bevacizumab, Bevacizumab in combination with the FOLFOX4 regimen, and FOLFOX4 alone as stated in commitment number 17 of the February 26, 2004, approval letter.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We reference the deferral granted on February 26, 2004, for the pediatric study requirement for this application until December 31, 2006.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. The final printed labeling (FPL) must be identical to the enclosed labeling text dated June 19, 2006. Marketing product with FPL that is not identical to the approved labeling may render the product misbranded and an unapproved new drug. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

Please submit content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed labeling text dated June 19, 2006. Upon receipt and verification, we will transmit that version to the National Library of Medicine for posting on the DailyMed website.

In addition, you may wish to submit draft copies of the proposed introductory advertising and promotional labeling with a cover letter requesting advisory comments to the Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising and Communication, 5901-B Ammendale Road, Beltsville, MD 20705-1266. Final

printed advertising and promotional labeling should be submitted at the time of initial dissemination, accompanied by a FDA Form 2253.

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence to support that claim.

Please refer to http://www.fda.gov/cder/biologics/default.htm for important information regarding therapeutic biological products, including the addresses for submissions. Effective August 29, 2005, the new address for all submissions to this application is:

Food and Drug Administration
Center for Drug Evaluation and Research
Therapeutic Biological Products Document Room
5901-B Ammendale Road
Beltsville, Maryland 20705-1266

This information will be included in your biologics license application file.

Sincerely,

Patricia Keegan

Patricia Keegan, M.D.
Director
Division of Biologic Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure: Revised Labeling dated 6-19-06

**CONCURRENCE PAGE**

Letter Type: LETTER: Approval (AP)
LETTER: Fulfillment of PMC (FPC)
Summary Text: Clinical Supplmt. Efficacy - New/Expanded Indication
LETTER: Pediatric Deferral Granted (PDG)

REVIEW COMPLETION REQUIRED BY: RIS

SS Data Check:
- Place copy of Approval Ltr. with original signature concurrence page in Archival package behind the "Approval Materials" Tab after LAR (Licensing Action Recommendation).

RIS Data Check:
- Verify short summary – Ltr. & Submission screen should match.
- Check Letter for PMCs (if PMCs – add "PMCs – Approved With" special characteristic code.)
- Check if Major Approval – if so – add code.
- Perform Review Completion Process
- Milestone: Confirm Approved Status

cc: OODP/K. Weiss
OODP/R. Pazdur
OODP/G. Jones
DBOP/S. Sickafuse
DBOP/J. Summers
DBOP/J. Gootenberg
DBOP/P. Keegan
DBOP/C. Lee
OBS/M. Rothmann
OBS/Y. Shen
HFM-110/RIMS/R. Eastep
OND/John Jenkins
OND/Exec sec V. Kinsey
OND/C. O'Leary
HFD-005/Mike Jones
HFD-410/ODS/DSRCS(Medwatch)/K. Young
ODS/DDRE/R. Pratt
HFD-013/FOI/C. Doyle
HFD-013/FOI/A. Glover
HFD-240/OTCOM/ B. Poole
HFD-230/OTCOM/CDER WebMaster
HFI-20/Press/ L. Gelb
HFI-20/Press/ J. Brodsky
DDMAC/K. Gray
DDMAC/C. Broadnax
CDER-OCTAP960PM (PEDs e-mail account)

HFD-322/IPCB/E. Rivera-Martinez
HFD-123/DMA/K. Clouse
HFD-328/TFRB Blue File/Mike Smedley
OBP/S. Kozlowski
DBOP BLA file (hard copy)

History:Sickafuse:5-16-06:6-13-06: K. Townsend: 6.14.2006

File Name: N:DBOP/Sickafuse/Bevacizumab/efficacy supplements/125085_74/approval letter.doc

| Division | Name/Signature | Date |
|---|---|---|
| DBOP | Sickafuse | 6-20-06 |
| OODP/DBOP | Karen D. Jones | 6/20/06 |
| DBOP | P. Keegan | 6-20-06 |
| OODP/DBOP | K. Laubach | 6/23/06 |
| | | |
| | | |
| | | |
| | | |